Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43) - Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE...

Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Incysus Therapeutics Initiates Enrollment in Phase 1 Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly Diagnosed Glioblastoma NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...